Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8:15.

Article  PubMed  PubMed Central  Google Scholar 

Verstovsek S, Gotlib J, Mesa RA, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT‑I and -II pooled analyses. J Hematol Oncol. 2017;10:156.

Article  PubMed  PubMed Central  Google Scholar 

Kroger N, Giorgino T, Scott BL, et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood. 2015;125:3347–50.

Article  PubMed  PubMed Central  Google Scholar 

CIBMTR. summary slides. 2019. http://cibmtr.org.

Google Scholar 

Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29:392–7.

Article  PubMed  Google Scholar 

Guglielmelli P, Lasho TL, Rotunno G, et al. MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2018;36:310–8.

Article  CAS  PubMed  Google Scholar 

Tefferi A, Guglielmelli P, Lasho TL, et al. MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol. 2018; 1769–70.

Passamonti F, Giorgino T, Mora B, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017;31:2726–31.

Article  CAS  PubMed  Google Scholar 

Gagelmann N, Badbaran A, Salit RB, et al. Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation. Blood. 2023;141:2901–11.

CAS  PubMed  PubMed Central  Google Scholar 

Kröger N, Bacigalupo A, Barbui T, et al. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group. Lancet Haematol. 2024;11:e62–e74.

Article  PubMed  Google Scholar 

Gagelmann N, Ditschkowski M, Bogdanov R, et al. Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood. 2019;133:2233–42.

Article  CAS  PubMed  Google Scholar 

Polverelli N, Bonneville EF, de Wreede LC, et al. Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: a study on behalf of the chronic malignancies working party of EBMT. Am J Hematol. 2024;99:993–6.

Article  CAS  PubMed  Google Scholar 

Salit RB, Scott BL, Stevens EA, et al. Pre-hematopoietic cell transplant ruxolitinib in patients with primary and secondary myelofibrosis. Bone Marrow Transplant. 2020;55:70–6.

Article  CAS  PubMed  Google Scholar 

Gupta V, Kosiorek HE, Mead A, et al. Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: myeloproliferative disorders research consortium 114 study. Biol Blood Marrow Transplant. 2019;25:256–64.

Article  CAS  PubMed  Google Scholar 

Kroger N, Sbianchi G, Sirait T, et al. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. Leukemia. 2021;35:3551–60.

Article  PubMed  PubMed Central  Google Scholar 

Polverelli N, Hernández-Boluda JC, Czerw T, et al. Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a position paper on behalf of the chronic malignancies working party of the EBMT. Lancet Haematol. 2023;10:e59–e70.

Article  CAS  PubMed  Google Scholar 

Gagelmann N, Hobbs GS, Campodonico E, et al. Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: a global collaborative analysis. Am J Hematol. 2024;99:844–53.

Article  CAS  PubMed  Google Scholar 

Kröger N, Holler E, Kobbe G, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the chronic leukemia working party of the European group for blood and marrow transplantation. Blood. 2009;114:5264–70.

Article  PubMed  Google Scholar 

Robin M, Giannotti F, Deconinck E, et al. Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis. Biol Blood Marrow Transplant. 2014;20:1841–6.

Article  PubMed  Google Scholar 

Raj K, Eikema DJ, McLornan DP, et al. Family mismatched allogeneic stem cell transplantation for myelofibrosis: report from the chronic malignancies working party of European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019;25:522–8.

Article  PubMed  Google Scholar 

Kunte S, Rybicki L, Viswabandya A, et al. Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. Leukemia. 2022;36:856–64.

Article  CAS  PubMed  Google Scholar 

Shimoni ARV, Nagler A. Conditioning. The EBMT handbook. 2024. pp. 125–134.

Book  Google Scholar 

McLornan D, Szydlo R, Koster L, et al. Myeloablative and reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the chronic malignancies working party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019;25:2167–71.

Article  PubMed  Google Scholar 

Kim DH, Seo J, Shin DY, et al. Reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for patients with myelofibrosis. Blood Res. 2022;57:264–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gagelmann N, Salit RB, Schroeder T, et al. High molecular and Cytogenetic risk in Mmelofibrosis does not benefit from higher intensity conditioning before Hematopoietic cell transplantation: an international collaborative analysis. Hemasphere. 2022;6:e784.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Robin M, Porcher R, Wolschke C, et al. Outcome after transplantation according to reduced-intensity conditioning regimen in patients undergoing transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2016;22:1206–11.

Article  PubMed  Google Scholar 

Murthy GSG, Kim S, Estrada-Merly N, et al. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica. 2023;108:1900–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Robin M, Iacobelli S, Koster L, et al. Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the chronic malignancies working party of the EBMT. Bone Marrow Transplant. 2024. e-pub ahead of print 2024/03/16 21:43

Freyer CW, Babushok DV, Frey NV, et al. Low-dose total body irradiation added to fludarabine and busulfan reduced-intensity conditioning reduces graft failure in patients with myelofibrosis. Transplant Cell Ther. 2022;28:590–6.

Article  CAS  PubMed  Google Scholar 

Battipaglia G, Mauff K, Wendel L, et al. Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the chronic malignancies working party of the EBMT. Bone Marrow Transplant. 2021;56:1593–602.

Article  CAS  PubMed  Google Scholar